Health TrialsbyHealthPanel

Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease

ConditionMetabolic Dysfunction-Associated Steatotic Liver Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorShanghai East Hospital

About this trial

Evaluating the Effectiveness, Safety, and Feasibility of Stationary Ultra-Slow Running in Treating MASLD Patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Meeting the diagnostic criteria for MASLD.

Aged between 18 and 70 years (inclusive), regardless of gender.

Patients voluntarily participate in this clinical study, have signed the informed consent form, and agree to comply with all study requirements, including follow-up visits, examinations, and treatments.

Disqualifiers

Exclusion of other conditions causing liver injury, including alcoholic hepatitis, active hepatitis B or C virus infection, drug-induced hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, Wilson's disease, α1-antitrypsin deficiency, liver cancer (or family history of liver cancer), etc.

History of medication use for more than 2 weeks within the past year that may induce hepatic steatosis or steatohepatitis (e.g., amiodarone, methotrexate, systemic glucocorticoids, tetracycline, tamoxifen, estrogen exceeding hormone replacement doses, anabolic steroids, valproic acid, or other known hepatotoxins).

Use of hepatoprotective drugs (including but not limited to reduced glutathione, glucurolactone, glycyrrhizin preparations, nicotinamide, bifendate, liver-protecting tablets, silymarin, polyene phosphatidylcholine, S-adenosylmethionine, ursodeoxycholic acid, vitamin E, or other herbal medicines affecting liver function) within 4 weeks prior to enrollment.

Presence of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or history of liver transplantation at randomization or previously, or planned liver transplantation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • In-Place Slow Jogging

    Behavioral

    ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes.

Treatment groups

82 Participants
are divided into 2 treatment groups
Group A: In-Place Slow Jogging GroupExperimental treatment 1 intervention
Group B: Control GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Liver Stiffness Measurement (LSM)

Measure method：FibroScan

Time frame
Baseline, 3 months post-treatment
2

Controlled Attenuation Parameter(CAP)

Measure method：FibroScan

Time frame
Baseline, 3 months post-treatment

Secondary outcomes

1

Polysomnography metrics

Measure method:Polysomnography（PSG)

Time frame
Baseline, 3 months post-treatment
2

Height

Time frame
Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment
3

Body Weight

Time frame
Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment
4

Waist Circumference

Time frame
Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shanghai East Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: